BioXcel Therapeutics, Inc.
 
公司簡況
財務
派息紀錄
盈利預測
股權變動
ETF簡況
 
 
 
公司概覽
業務類別 --
業務概覽 BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology.The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
公司地址 555 Long Wharf Drive, New Haven, CT, USA, 06511
電話號碼 +1 475 238-6837
傳真號碼 +1 475 238-6837
公司網頁 https://www.bioxceltherapeutics.com
員工數量 29
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Richard I. Steinhart Senior Vice President, Chief Financial Officer and Principal Accounting Officer 美元 409.87K 27/03/2026
Dr. Vincent J. O'Neill, M.D. Executive Vice President, Chief of Product Development and Chief Medical Officer -- 29/04/2024
Dr. Vimal Mehta, PhD Director, Chief Executive Officer and President 美元 1.00M 27/03/2026
Dr. Frank D. Yocca, PhD Senior Vice President and Chief Scientific Officer -- 27/03/2026
Mr. Matthew T. Wiley Senior Vice President and Chief Commercial Officer 美元 445.20K 19/09/2024
Mr. Javier Rodriguez Senior Vice President, Chief Legal Officer and Corporate Secretary 美元 423.83K 27/03/2026
 
董事會成員
董事會 職務 更新日期
Dr. Peter Mueller,PhD Chairman of the Board 27/03/2026
Dr. Rajiv Patni, M.D. Director 27/03/2026
Mr. David J. Mack Independent Director 27/03/2026
Dr. Michal Votruba, M.D.,PhD Independent Director 27/03/2026
Dr. Sandeep Laumas, M.D. Independent Director 27/03/2026
Dr. Vimal Mehta, PhD Director, Chief Executive Officer and President 27/03/2026
Dr. Krishnan Nandabalan, PhD Director 17/05/2023
Ms. June Bray Independent Director 27/03/2026
Mr. Michael Miller Independent Director 27/03/2026
 
所屬ETF (更新日期: 08/09/2026 07:30)
代號 名稱 佔比% ▼ 持有日期
IWCiShares Micro-Cap ETF0.28%31/08/2026
AVSCAvantis® US Small Cap Equity ETF0.004%29/07/2023
STXKStrive 2000 ETF0.0001%30/12/2022
AVSCAvantis US Small Cap Equity ETF<0.000001%01/08/2023
AVSUAvantis Responsible US Equity ETF<0.000001%21/09/2022
AVUSAvantis US Equity ETF<0.000001%13/06/2023
AVUSAvantis® U.S. Equity ETF<0.000001%13/06/2023
BBCVirtus LifeSci Biotech Clinical Trls ETF<0.000001%18/12/2023
BBSCJPMorgan BetaBuilders US Sml Cp Eq ETF<0.000001%21/06/2022
DFACDimensional US Core Equity 2 ETF<0.000001%08/08/2023
DFASDimensional US Small Cap ETF<0.000001%14/09/2023
DFATDimensional US Targeted Value ETF<0.000001%20/01/2023
DFAUDimensional US Core Equity Market ETF<0.000001%16/06/2023
DFSUDimensional US Sustainability Core 1 ETF<0.000001%08/08/2023
FBCGFidelity® Blue Chip Growth ETF<0.000001%31/05/2021
FHLCFidelity MSCI Health Care ETF<0.000001%02/12/2023
FHLCFidelity® MSCI Health Care ETF<0.000001%02/12/2023
GSSCGoldman Sachs ActiveBeta® US SmCp Eq ETF<0.000001%18/09/2023
GUGGuggenheim Active Allocation Fund<0.000001%28/02/2023
HDGProShares Hedge Replication<0.000001%01/07/2024
 1    2    3  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.